Letter: distinct hepatitis B virus relapse rates after discontinuing tenofovir and entecavir therapy in chronic hepatitis B patients-author's reply

Aliment Pharmacol Ther. 2019 Apr;49(8):1106-1107. doi: 10.1111/apt.15183.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antiviral Agents*
  • Guanine / analogs & derivatives
  • Hepatitis B virus
  • Hepatitis B, Chronic*
  • Humans
  • Recurrence
  • Tenofovir

Substances

  • Antiviral Agents
  • entecavir
  • Guanine
  • Tenofovir